SGLT2 inhibition has been recognized as a novel and safe approach to lowering high glucose levels in T2D and several SGLT2 inhibitors were developed and tested in clinical trials [7], [8]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.